Fri, Nov 28, 2014, 9:51 AM EST - U.S. Markets close early today in 3 hrs 9 mins for The day after Thanksgiving


% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

woodbarn 4 posts  |  Last Activity: Oct 4, 2014 5:20 AM Member since: May 9, 1999
  • woodbarn woodbarn Oct 4, 2014 5:20 AM Flag

    AssemblyBio's molecules might be in the class of heteroaryldihydropyrimidines (HAPs) or has a chemical structure that is similar. Zlotnick co-authored an article in 2006 titled, "BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly." BAY 41-4109 was an early (HAPs) drug from the company Bayer which either was not tested in humans or did not get further than phase 1.

    There is also another article by seven researchers which included Zlotnick from 2008 titled, "Small-Molecule Effectors of Hepatitis B Virus Capsid Assembly Give Insight into Virus Life Cycle," in which 18 derived (HAPs) were compared for effectiveness.

    AssemblyBio has not revealed their drug or structure or even announced it yet. So this is all just guessing.

  • woodbarn woodbarn Oct 3, 2014 4:05 PM Flag

    Zlotnick, the lead researcher at AssemblyBio, co-authored in the year 2002 an article titled, "A small molecule inhibits and misdirects assembly of hepatitis B virus capsids." So calling the drug an "HBV capsid assembly inhibitor" is probably correct. I think "allosterically modifying core protein" describes what the "capsid assembly inhibitor" drug does. cccDNA target is over a decade old, so one would assume others might be researching it.

    I found two companies in United States working on "capsid assembly inhibitors". Novira Therapeutics is in phase 1, which was started mid-2014. Enantigen is pre-clinical. Enantigen was recently acquired. AssemblyBio is already behind Novira.

    There is also a company in China in phase 2 with a "capsid assembly inhibitor". But that is for China market.

    Anyway, it will take years for HBV market players to play out. So just be aware that there are competitors and that AssemblyBio now calls their drug "best-in-class" instead of "first-in-class".

  • HBV drug has potential, but other companies also researching same target. Before the merger the drug was called "first in class", which implies they are at the fore-front with little competition. Notice after the merger the drug is described as "best in class", which implies they are the best out of a group. I guess AssemblyBio management did some searching around and found other companies also researching HBV capsid assembly inhibitors.

    Seeing that there is little information on competitor's drug it is misleading to describe their drug as "best in class" of capsid assembly inhibitors. I was disappointed to find other companies researching the same target. So it is now a race between a couple of companies. So assuming drug class works, a couple of drugs might have to share the market.

  • Minor old news: Protalix completed Elelyso clinical trials September 9, 2014. Two Elelyso clinical trials were changed to completed at So Protalix finished up Elelyso studies and can now focus attention and resources on Fabry and oral Anti-TNF.

2.0843-0.0257(-1.22%)9:48 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.